CFO appointment
MBX Biosciences, Inc. appoints John Smither as CFO
MBX Biosciences, Inc. reported in a Form 8-K filed July 13, 2026 that John Smither was appointed Chief Financial Officer and principal financial officer, effective July 13, 2026.
In the filing's words
On July 9, 2026, the Board appointed John Smither, the Company’s current interim Chief Financial Officer, as Chief Financial Officer and principal financial officer of the Company, effective as of July 13, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | MBX Biosciences, Inc. (MBX) |
|---|---|
| Event | Appointment |
| Incoming | John Smither |
| Title in the filing | Chief Financial Officer and principal financial officer |
| Effective | July 13, 2026 |
| 8-K filed | July 13, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | interim Chief Financial Officer, MBX Biosciences, Inc. |
| SEC CIK | 0001776111 |
MBX Biosciences, Inc. reported this change in a Form 8-K, Item 5.02, filed July 13, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about John Smither? Send a correction with the primary source.